Profile data is unavailable for this security.
About the company
Immunovant, Inc. is a clinical-stage immunology company. The Company is focused on developing treatments for patients with autoimmune diseases. Its product pipeline includes batoclimab and IMVT-1402, both of which are novel, fully human monoclonal antibodies that target the neonatal fragment crystallizable receptor (FcRn). Batoclimab is a subcutaneous injection with dosing. Batoclimab is observed to reduce immunoglobulin G (IgG) antibodies that cause inflammation and disease. Its product candidate, batoclimab, is dosed in small volumes and with a 27-gauge needle. It is developing batoclimab for myasthenia gravis (MG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP) and Graves’ disease (GD). Its lead product candidate IMVT-1402 has also been observed to reduce IgG antibody levels in a Phase I clinical trial conducted in healthy adults. IMVT-1402 is a fully human monoclonal antibody that inhibits FcRn.
- Revenue in USD (TTM)0.00
- Net income in USD-272.55m
- Incorporated2018
- Employees207.00
- LocationImmunovant Inc320 West 37Th StreetNEW YORK 10018United StatesUSA
- Phone+1 (917) 580-3099
- Fax+1 (302) 636-5454
- Websitehttps://immunovant.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amicus Therapeutics, Inc. | 455.66m | -119.54m | 3.24bn | 517.00 | -- | 24.40 | -- | 7.10 | -0.397 | -0.397 | 1.51 | 0.4471 | 0.6159 | 0.6948 | 6.12 | 881,344.30 | -16.16 | -30.65 | -20.75 | -36.55 | 89.88 | 88.94 | -26.23 | -86.10 | 2.26 | -0.6134 | 0.7459 | -- | 21.30 | 34.35 | 35.92 | -- | 3.36 | -- |
| Rhythm Pharmaceuticals Inc | 101.78m | -260.73m | 3.28bn | 226.00 | -- | 83.30 | -- | 32.22 | -4.37 | -4.37 | 1.71 | 2.94 | 0.2943 | 1.25 | 6.48 | 450,367.30 | -75.00 | -47.21 | -87.80 | -52.84 | 88.80 | -- | -254.88 | -681.38 | 6.31 | -- | 0.3765 | -- | 227.56 | -- | -1.97 | -- | -42.10 | -- |
| Alvotech SA | 308.73m | -618.38m | 3.34bn | 999.00 | -- | -- | -- | 10.81 | -2.65 | -2.65 | 1.28 | -2.27 | 0.312 | 1.80 | 3.66 | 309,038.00 | -62.49 | -- | -222.85 | -- | 48.79 | -- | -200.30 | -- | 0.1569 | -0.2323 | 2.04 | -- | 9.84 | -- | -7.43 | -- | -- | -- |
| MoonLake Immunotherapeutics | 0.00 | -54.80m | 3.39bn | 50.00 | -- | 6.41 | -- | -- | -0.9043 | -0.9043 | 0.00 | 8.28 | 0.00 | -- | -- | 0.00 | -11.08 | -- | -11.49 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 27.95 | -- | -- | -- |
| Dyne Therapeutics Inc | 0.00 | -257.60m | 3.45bn | 152.00 | -- | 4.44 | -- | -- | -3.58 | -3.58 | 0.00 | 7.74 | 0.00 | -- | -- | 0.00 | -47.82 | -52.81 | -50.15 | -57.45 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -40.36 | -- | 40.32 | -- |
| Biohaven Ltd | 0.00 | -746.61m | 3.72bn | 239.00 | -- | 9.48 | -- | -- | -9.15 | -9.15 | 0.00 | 4.16 | 0.00 | -- | -- | 0.00 | -137.07 | -- | -176.64 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 28.43 | -- | -- | -- |
| TG Therapeutics Inc | 346.73m | 95.69m | 3.91bn | 300.00 | 42.08 | 22.02 | 40.79 | 11.27 | 0.6001 | 0.6001 | 2.29 | 1.15 | 1.11 | 0.4505 | 6.86 | 1,313,356.00 | 30.76 | -62.87 | 43.42 | -80.06 | 92.76 | -- | 27.60 | -405.03 | 2.83 | 8.21 | 0.3661 | -- | 8,290.02 | 333.86 | 106.39 | -- | -- | -- |
| Crinetics Pharmaceuticals Inc | 1.39m | -258.54m | 4.22bn | 290.00 | -- | 5.04 | -- | 3,049.44 | -3.77 | -3.77 | 0.0201 | 10.47 | 0.0023 | -- | 0.4157 | 4,775.86 | -41.16 | -42.53 | -44.29 | -45.36 | -- | -- | -18,257.91 | -5,446.39 | -- | -- | 0.00 | -- | -15.28 | 10.57 | -30.88 | -- | 34.65 | -- |
| Immunovant Inc | 0.00 | -272.55m | 4.23bn | 207.00 | -- | 7.76 | -- | -- | -1.92 | -1.92 | 0.00 | 3.73 | 0.00 | -- | -- | 0.00 | -57.93 | -- | -64.54 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -22.93 | -- | -- | -- |
| Arcellx Inc | 144.75m | -53.89m | 4.33bn | 130.00 | -- | 8.87 | -- | 29.91 | -1.05 | -1.05 | 2.84 | 9.08 | 0.2132 | -- | -- | 1,113,423.00 | -7.94 | -38.82 | -9.68 | -45.41 | -- | -- | -37.23 | -339.38 | -- | -- | 0.038 | -- | -- | -- | 62.53 | -- | 113.86 | -- |
| Denali Therapeutics Inc | 1.27m | -419.65m | 4.40bn | 364.00 | -- | 3.17 | -- | 3,475.74 | -2.85 | -2.85 | 0.0085 | 9.69 | 0.0009 | -- | -- | 2,847.19 | -29.89 | -14.98 | -31.50 | -17.71 | -- | -- | -33,121.86 | -104.50 | -- | -- | 0.00 | -- | 204.74 | 20.67 | 55.45 | -- | 30.70 | -- |
| Alkermes Plc | 1.51bn | 457.54m | 4.58bn | 2.10k | 10.41 | 3.60 | 9.00 | 3.04 | 2.67 | 1.69 | 8.78 | 7.74 | 0.6864 | 1.31 | 4.28 | 718,055.30 | 20.83 | 1.34 | 26.98 | 1.74 | 83.31 | 83.32 | 30.34 | 2.12 | 2.61 | -- | 0.184 | 0.00 | 49.61 | 8.74 | 1,665.99 | -- | -7.10 | -- |
| Madrigal Pharmaceuticals Inc | 14.64m | -510.45m | 5.06bn | 376.00 | -- | 5.90 | -- | 345.85 | -25.50 | -25.50 | 0.7351 | 39.50 | 0.0209 | -- | -- | 38,930.85 | -72.80 | -62.09 | -86.71 | -74.81 | 95.66 | -- | -3,487.13 | -- | 8.67 | -- | 0.1198 | -- | -- | -- | -26.50 | -- | 132.01 | -- |
| Krystal Biotech Inc | 166.23m | 105.94m | 5.25bn | 229.00 | 50.02 | 6.25 | 46.53 | 31.58 | 3.65 | 3.65 | 5.70 | 29.22 | 0.2076 | -- | -- | 725,908.30 | 13.23 | -11.50 | 14.07 | -12.01 | 93.07 | -- | 63.73 | -492.85 | 9.33 | -- | 0.00 | -- | -- | -- | 107.81 | -- | 39.49 | -- |
Data as of Sep 19 2024. Currency figures normalised to Immunovant Inc's reporting currency: US Dollar USD
26.01%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 30 Jun 2024 | 10.48m | 7.16% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 6.34m | 4.33% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 4.26m | 2.91% |
| Armistice Capital LLCas of 30 Jun 2024 | 3.40m | 2.32% |
| Deep Track Capital LPas of 30 Jun 2024 | 2.88m | 1.97% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 2.72m | 1.86% |
| Viking Global Investors LPas of 30 Jun 2024 | 2.32m | 1.59% |
| Perceptive Advisors LLCas of 30 Jun 2024 | 1.92m | 1.31% |
| Alpine Global Management LLCas of 30 Jun 2024 | 1.91m | 1.30% |
| Woodline Partners LPas of 30 Jun 2024 | 1.82m | 1.25% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
